Zuclopenthixol Decanoate Injection
- Packing: 1 Ml Ampoule.
- Available Strength : 200 Mg/Ml
Description
Product Description: Zuclopenthixol Decanoate Injection is a sterile, aqueous suspension containing zuclopenthixol decanoate, a long-acting injectable antipsychotic medication. It is indicated for the treatment of schizophrenia and other psychotic disorders.
Indications and Usage: Zuclopenthixol Decanoate Injection is indicated for the management of symptoms associated with schizophrenia and other psychotic disorders, including hallucinations, delusions, disorganized thinking, and agitation.
Dosage and Administration: The dosage of Zuclopenthixol Decanoate Injection varies depending on the severity of symptoms, the patient's response to treatment, and previous antipsychotic therapy. It is administered via deep intramuscular injection by a healthcare professional at regular intervals, typically every 2 to 4 weeks.
Dosage Forms and Strengths: Zuclopenthixol Decanoate Injection is available as a sterile suspension in vials or pre-filled syringes. The strength of the suspension is typically expressed in milligrams of zuclopenthixol decanoate per milliliter (mg/mL), with various concentrations available to accommodate different dosing regimens.
Contraindications: Zuclopenthixol Decanoate Injection is contraindicated in patients with a known hypersensitivity to zuclopenthixol or any component of the formulation. It should not be used in patients with severe central nervous system depression, comatose states, or conditions predisposing to convulsions.
Warnings and Precautions: Use caution when administering Zuclopenthixol Decanoate Injection in elderly patients, patients with cardiovascular disease, or those at risk of developing QT prolongation or neuroleptic malignant syndrome. Monitor patients closely for signs of extrapyramidal symptoms, tardive dyskinesia, hyperglycemia, and orthostatic hypotension.
Adverse Reactions/Side Effects: Common adverse reactions associated with Zuclopenthixol Decanoate Injection may include sedation, drowsiness, dizziness, extrapyramidal symptoms (such as parkinsonism, dystonia, and akathisia), weight gain, and anticholinergic effects. Rare but serious adverse reactions may include neuroleptic malignant syndrome, tardive dyskinesia, and QT prolongation.
Drug Interactions: Zuclopenthixol Decanoate Injection may interact with other medications that affect the central nervous system or prolong the QT interval, suchas antidepressants, antipsychotics, and certain antibiotics. Concurrent use may potentiate or antagonize the effects of zuclopenthixol, leading to increased or decreased efficacy or adverse reactions. Use caution and monitor patients closely for signs of drug interactions.
Use In Specific Populations Description: Safety and efficacy of Zuclopenthixol Decanoate Injection in pediatric patients, elderly patients, pregnant women, and nursing mothers have not been established conclusively. Use caution and individualize the dosage and administration based on the patient's age, weight, and medical condition.
How Supplied/Storage and Handling: Zuclopenthixol Decanoate Injection is supplied as a sterile suspension in vials or pre-filled syringes for intramuscular administration. It should be stored at controlled room temperature (20°C to 25°C) away from light and moisture. Care should be taken to ensure proper storage and handling to maintain the integrity of the product. Unused portions should be discarded according to standard procedures for biohazardous waste.
